



Advanced in Schizophrenia Research and Treatment

Guest Editor:

Dr. Felix-Martin Werner

Institute of Neuroscience of
Castilla and León (INCYL)
Laboratory, Universidad de
Salamanca, Salamanca, Spain

Deadline for manuscript
submissions:

31 July 2025

Message from the Guest Editor

Dear Colleagues,

Schizophrenia and schizoaffective disorder are disabling mental diseases that may manifest as a recurrent psychosis. Therefore, their treatment with antipsychotic drugs is essential. Adverse effects (for example, movement disturbances, and metabolic and cardiac adverse effects) reduce patients' adherence to medical treatment. In recent years, new antipsychotic drugs that interact with new specific receptors have been found and applied to the treatment of this disease. Have these new antipsychotic drugs made progress in the treatment of schizophrenic symptoms? Have they caused fewer adverse effects? Have they had a secure therapeutic effect? Has patients' adherence become more reliable, and have their schizophrenic symptoms therefore been treated better? Have therapeutic measures outside of pharmacological treatment made progress in the medical treatment of these symptoms? Your research papers and comprehensive reviews regarding these questions are warmly welcomed.

Dr. Felix-Martin Werner

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)